2024年5月20日 · TP53 mutations are found in 5%-10% of de novo myelodysplastic syndrome (MDS) and AML cases. By contrast, in therapy related MDS and AML, mutations in TP53 are found in up to 30%-40% of patients. The majority of inactivating mutations observed in MDS and AML are missense mutations localized in a few prevalent hotspots.

The vast majority of de novo acute myeloid leukemia (AML) present unaltered TP53 alleles. However, TP53 mutations are frequently detected in AML related to an increased genomic instability, such as therapy‐related (t-AML) or AML with myelodysplasia-related changes.

2024年11月19日 · TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of patients with de novo...

2025年3月4日 · Patients with acute myeloid leukemia (AML) harboring mutations in TP53 (TP53 -MT) have poor responses to current therapies and unfavorable prognoses. Despite the recognition of variant TP53 as an adverse feature of AML, an optimal treatment regimen has not yet been established, underlining a critical need for new, more effective therapeutic combinations and novel treatments. We present the ...

TP53 mutations are associated with a very poor prognosis and define a unique disease subgroup within AML. TP53 -mutated AML often shows limited response to conventional chemotherapy and even allogeneic hematopoietic stem cell transplantation.

2023年2月18日 · TP53 mutated (m) acute myeloid leukemia (AML) is associated with high relapse rate and poor overall survival (OS) [1, 2, 3]. Response to cytotoxic chemotherapy is highly dependent on the...

2022年4月14日 · Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients.

The mutational status of TP53 therefore poses challenges and opportunities in terms of advancing effective treatment strategies in AML. An increasing armamentarium of small-molecule activators of the TP53 pathway, and a growing understanding of molecular pathways triggered by mutant TP53 have accelerated efforts aimed at targeting TP53 function ...

2024年12月26日 · TP53突变见于约5%-10%的新发急性髓系白血病 (AML) 患者，在老年患者和治疗相关 AML 患者中更常见。 尽管最近在分子特征和靶向治疗方面取得了进展，但 TP53 突变 AML 仍存在巨大的治疗挑战。 目前的治疗策略包括常规化疗、去甲基化药物和基于维奈克拉的治疗，在 TP53 突变 AML 中疗效有限，缓解率低，总生存期差。 异基因造血干细胞移植是一种可能治愈的选择，但其在 TP53 突变 AML 中的疗效还取决于移植时的合并症和疾病状态。 包括免疫疗法 …

2024年11月5日 · TP53 mutation in acute myeloid leukemia is known to poor outcomes and response to standard treatments. This study aimed to provide a detailed characterization of TP53 - mutated AML focusing on its distinct clinical and molecular features.